CSPC Pharmaceutical Group Limited (CSPCY)
USD 3.05
(-2.71%)
USD 3.05
(-2.71%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 31.45 Billion CNY | 1.66% |
| 2022 | 30.93 Billion CNY | 11.02% |
| 2021 | 27.86 Billion CNY | 11.73% |
| 2020 | 24.94 Billion CNY | 12.84% |
| 2019 | 22.1 Billion CNY | 19.68% |
| 2018 | 18.46 Billion HKD | 42.94% |
| 2017 | 12.92 Billion HKD | 16.66% |
| 2016 | 11.07 Billion HKD | 16.08% |
| 2015 | 9.54 Billion HKD | 8.91% |
| 2014 | 8.76 Billion HKD | 12.68% |
| 2013 | 7.77 Billion HKD | 132.85% |
| 2012 | 3.33 Billion HKD | -44.1% |
| 2011 | 5.97 Billion HKD | -9.86% |
| 2010 | 6.62 Billion HKD | 7.02% |
| 2009 | 6.19 Billion HKD | 2.95% |
| 2008 | 6.01 Billion HKD | 28.75% |
| 2007 | 4.67 Billion HKD | 31.64% |
| 2006 | 3.54 Billion HKD | 6.79% |
| 2005 | 3.32 Billion HKD | 27.26% |
| 2004 | 2.61 Billion HKD | -1.2% |
| 2003 | 2.64 Billion HKD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 8.98 Billion CNY | 18.43% |
| 2024 Q2 | 7.3 Billion CNY | 0.0% |
| 2023 Q4 | 7.58 Billion CNY | -2.56% |
| 2023 Q2 | 8.02 Billion CNY | -0.32% |
| 2023 Q1 | 8.05 Billion CNY | 8.22% |
| 2023 FY | 31.45 Billion CNY | 1.66% |
| 2023 Q3 | 7.78 Billion CNY | -3.02% |
| 2022 Q3 | 7.88 Billion CNY | 1.93% |
| 2022 FY | 30.93 Billion CNY | 11.02% |
| 2022 Q1 | 7.87 Billion CNY | -11.17% |
| 2022 Q2 | 7.73 Billion CNY | -1.75% |
| 2022 Q4 | 7.44 Billion CNY | -5.63% |
| 2021 Q4 | 8.86 Billion CNY | 7.68% |
| 2021 FY | 27.86 Billion CNY | 11.73% |
| 2021 Q3 | 8.23 Billion CNY | -3.42% |
| 2021 Q1 | 7.98 Billion CNY | 17.46% |
| 2021 Q2 | 8.52 Billion CNY | 6.7% |
| 2020 Q1 | 6.7 Billion CNY | 12.14% |
| 2020 Q4 | 6.8 Billion CNY | -10.06% |
| 2020 FY | 24.94 Billion CNY | 12.84% |
| 2020 Q3 | 7.56 Billion CNY | 6.64% |
| 2020 Q2 | 7.09 Billion CNY | 5.76% |
| 2019 Q1 | 6.42 Billion CNY | 23.39% |
| 2019 Q3 | 6.12 Billion CNY | -5.32% |
| 2019 Q4 | 5.97 Billion CNY | -2.35% |
| 2019 FY | 22.1 Billion CNY | 19.68% |
| 2019 Q2 | 6.46 Billion CNY | 0.65% |
| 2018 Q1 | 5.47 Billion CNY | 28.64% |
| 2018 Q2 | 5.19 Billion CNY | -5.04% |
| 2018 Q3 | 4.99 Billion CNY | -3.88% |
| 2018 Q4 | 5.2 Billion CNY | 4.23% |
| 2018 FY | 18.46 Billion HKD | 42.94% |
| 2017 FY | 12.92 Billion HKD | 16.66% |
| 2017 Q4 | 4.25 Billion CNY | 6.2% |
| 2017 Q3 | 4 Billion CNY | 7.39% |
| 2017 Q2 | 3.73 Billion CNY | 7.48% |
| 2017 Q1 | 3.47 Billion CNY | 11.29% |
| 2016 Q3 | 3.1 Billion CNY | -1.52% |
| 2016 Q4 | 3.11 Billion CNY | 0.46% |
| 2016 Q2 | 3.15 Billion CNY | 5.32% |
| 2016 FY | 11.07 Billion HKD | 16.08% |
| 2016 Q1 | 2.99 Billion CNY | 3.55% |
| 2015 Q4 | 2.89 Billion CNY | 4.26% |
| 2015 FY | 9.54 Billion HKD | 8.91% |
| 2015 Q3 | 2.77 Billion CNY | -5.96% |
| 2015 Q2 | 2.94 Billion CNY | 5.97% |
| 2015 Q1 | 2.78 Billion CNY | -1.22% |
| 2014 Q4 | 2.81 Billion CNY | 0.73% |
| 2014 FY | 8.76 Billion HKD | 12.68% |
| 2014 Q1 | 2.58 Billion CNY | 2.63% |
| 2014 Q2 | 2.75 Billion CNY | 6.87% |
| 2014 Q3 | 2.79 Billion CNY | 1.31% |
| 2013 Q4 | 2.51 Billion CNY | 6.75% |
| 2013 FY | 7.77 Billion HKD | 132.85% |
| 2013 Q3 | 2.35 Billion CNY | -6.73% |
| 2013 Q2 | 2.52 Billion CNY | -0.84% |
| 2013 Q1 | 2.54 Billion CNY | 0.0% |
| 2012 FY | 3.33 Billion HKD | -44.1% |
| 2011 FY | 5.97 Billion HKD | -9.86% |
| 2010 FY | 6.62 Billion HKD | 7.02% |
| 2009 FY | 6.19 Billion HKD | 2.95% |
| 2008 FY | 6.01 Billion HKD | 28.75% |
| 2007 FY | 4.67 Billion HKD | 31.64% |
| 2006 FY | 3.54 Billion HKD | 6.79% |
| 2005 FY | 3.32 Billion HKD | 27.26% |
| 2004 FY | 2.61 Billion HKD | -1.2% |
| 2003 FY | 2.64 Billion HKD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AstraZeneca PLC | 46.91 Billion USD | 32.963% |
| Bristol-Myers Squibb Company PFD CONV 2 | 45 Billion USD | 30.12% |
| CSPC Pharmaceutical Group Limited | 31.45 Billion USD | 0.0% |
| Clarus Therapeutics Holdings, Inc. | 13.95 Million USD | -225235.738% |
| Novartis AG | 46.66 Billion USD | 32.597% |
| PT Kalbe Farma Tbk. | 1.97 Billion USD | -1489.036% |